Literature DB >> 21275592

Understanding Rasch and item response theory models: applications to the estimation and validation of interval latent trait measures from responses to rating scale questionnaires.

Robert W Massof1.   

Abstract

BACKGROUND: Modern psychometric theory is now routinely used in clinical vision research, as well as other areas of health research, to measure latent health states on continuous interval scales from responses to self-report rating scale questionnaires. Two competing theories are commonly employed: Rasch theory and item response theory.
METHODS: Because the field is currently in transition from using traditional scoring algorithms based on classical test theory to using the more modern approaches, this article offers a tutorial review of Rasch theory and item response theory and of the analytical methods employed by the two theories to estimate and validate measures.

Mesh:

Year:  2011        PMID: 21275592     DOI: 10.3109/09286586.2010.545501

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  20 in total

1.  Further validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in the UK veterinary profession: Rasch analysis.

Authors:  David J Bartram; Julia M Sinclair; David S Baldwin
Journal:  Qual Life Res       Date:  2012-03-02       Impact factor: 4.147

2.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

3.  Glaucoma-Associated Visual Task Performance and Vision-Related Quality of Life in South India.

Authors:  Chelsea L Reighard; Manju R Pillai; Sujani Shroff; George L Spaeth; Stephen G Schilling; Sheryl S Wizov; Joshua D Stein; Alan L Robin; Vidya Raja; Joshua R Ehrlich
Journal:  Ophthalmol Glaucoma       Date:  2019-06-18

4.  Measurements of street-crossing decision-making in pedestrians with low vision.

Authors:  Shirin E Hassan; Robert W Massof
Journal:  Accid Anal Prev       Date:  2012-04-05

Review 5.  Patient-Centered Outcome Measures to Assess Functioning in Randomized Controlled Trials of Low-Vision Rehabilitation: A Review.

Authors:  Joshua R Ehrlich; George L Spaeth; Noelle E Carlozzi; Paul P Lee
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

6.  Interpretation of low-vision rehabilitation outcome measures.

Authors:  Robert W Massof; Joan A Stelmack
Journal:  Optom Vis Sci       Date:  2013-08       Impact factor: 1.973

7.  Calibration of the Activity Inventory Item Bank: A Patient-Reported Outcome Measurement Instrument for Low Vision Rehabilitation.

Authors:  Micaela Gobeille; Chris Bradley; Judith E Goldstein; Robert Massof
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

8.  Fear of falling in age-related macular degeneration.

Authors:  Suzanne W van Landingham; Robert W Massof; Emilie Chan; David S Friedman; Pradeep Y Ramulu
Journal:  BMC Ophthalmol       Date:  2014-01-28       Impact factor: 2.209

9.  Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up.

Authors:  Dorothea Peters; Anders Heijl; Lena Brenner; Boel Bengtsson
Journal:  Acta Ophthalmol       Date:  2015-09-18       Impact factor: 3.761

10.  Development of a rapid point-of-care patient reported outcome measure for cataract surgery in India.

Authors:  Joshua R Ehrlich; Charlie Frank; Josiah Smiley; Hong-Gam Le; Sanil Joseph; Stephen G Schilling; Brian C Stagg; Joshua D Stein; R D Ravindran; Aravind Haripriya
Journal:  Health Qual Life Outcomes       Date:  2018-01-30       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.